Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2019

View Archived Issues

Loss of function of ADAR1 in tumor cells as a new strategy to overcome immunotherapy resistance

Nanoscavenger versus neurotoxins

Chemotherapy can facilitate metastases

Mavupharma names its first immuno-oncology clinical development candidate

AbbVie and Tizona Therapeutics to jointly develop CD-39-targeted therapeutics

NLRC5, a new diagnostic marker of IgA nephritis and its progression

Bionomics initiates phase II MODULATE study of BNC-105 in combination with nivolumab

Lundbeck initiates phase II study of Lu-AF-11167 for the treatment of schizophrenia

Obesity may be linked to anxiety via senescence

Pse-T2 shows promising activity in a mouse wound model infected with MDR strains

Positive topline results presented from first cohort of phase I/II study of DTX-401

CHDI-390576, a novel CNS-penetrant benzhydryl hydroxamic acid class IIa HDAC inhibitor

Phase I results reported for oral ferroportin inhibitor VIT-2763

Gilead and Yuhan enter licensing and collaboration agreement to treat NASH-related fibrosis

PRKCD targeting found useful against EGFR inhibitor-resistant lung cancer

Galapagos initiates phase I trial with GLPG-3312

Valneva announces promising phase I interim data on Chikungunya vaccine candidate VLA-1553

Galapagos initiates phase IIa study of GLPG-1690 in systemic sclerosis

Jazz and Codiak collaborate on exosome therapeutics to treat cancer

FDA clears IND for phase I trial of ARV-110 in metastatic castration-resistant prostate cancer

Adaptive Biotechnologies and Genentech collaborate on neoantigen-directed T-cell cancer therapies

Regulus reports preliminary interim data from mouse chronic toxicity study of RGLS-4326

KCI-807 compound discovered as an androgen receptor function disruptor in prostate cancer

Idorsia begins multiple-dose study of cenerimod for SLE

Sojournix completes financing to advance SJX-653 for menopausal vasomotor symptoms